Comparative Pharmacology
Head-to-head clinical analysis: BUTAZOLIDIN versus DICLOFENAC POTASSIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTAZOLIDIN versus DICLOFENAC POTASSIUM.
BUTAZOLIDIN vs DICLOFENAC POTASSIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis. Also has uricosuric effect at higher doses.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates pain, inflammation, and fever.
Butazolidin (phenylbutazone) is typically administered orally at 100-200 mg 3 times daily with meals, not to exceed 600 mg/day. Initial loading dose of 400 mg may be given on day 1, followed by 300-400 mg/day in divided doses. Duration should be limited to 7-10 days.
50 mg orally twice daily or 75 mg orally once daily; maximum 150 mg/day. Alternatively, 75 mg intramuscularly once daily (short-term).
None Documented
None Documented
Terminal half-life: 50-100 hours (prolonged in elderly or hepatic/renal impairment; accumulation risk evident within 5-7 days).
Terminal elimination half-life is ~1.1 hours (range 0.9–1.6 h). Short half-life supports frequent dosing (e.g., every 6–8 hours) for sustained analgesia.
Primarily renal: ~60% as unchanged drug and glucuronide conjugates; biliary/fecal: ~40% (enterohepatic circulation).
Approximately 50% of a dose is eliminated via first-pass hepatic metabolism; renal excretion accounts for ~65% of the administered dose as metabolites (<1% unchanged drug); fecal excretion <20%.
Category C
Category D/X
NSAID
NSAID